These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27181566)

  • 21. Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials.
    Dangas GD; Schoos MM; Steg PG; Mehran R; Clemmensen P; van 't Hof A; Prats J; Bernstein D; Deliargyris EN; Stone GW
    Circ Cardiovasc Interv; 2016 May; 9(5):e003272. PubMed ID: 27165710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
    Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
    J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
    Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
    Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
    Exaire JE; Butman SM; Ebrahimi R; Kleiman NS; Harrington RA; Schweiger MJ; Bittl JA; Wolski K; Topol EJ; Lincoff AM;
    Am Heart J; 2006 Jul; 152(1):157-63. PubMed ID: 16824849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
    Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R
    JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
    J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
    Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
    Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
    Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
    Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators).
    Kumar D; Dangas G; Mehran R; Kirtane A; Bertrand M; Ebrahimi R; Guagliumi G; Brar S; Fahy M; Heller E; Moses J; Stone G
    Am J Cardiol; 2010 Oct; 106(7):941-5. PubMed ID: 20854954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial.
    Schoos MM; De Luca G; Dangas GD; Clemmensen P; Ayele GM; Mehran R; Stone GW
    EuroIntervention; 2016 Oct; 12(9):1144-1153. PubMed ID: 27753600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.
    Ibebuogu UN; Bolorunduro O; Giri S; Dagogo-Jack S; Smith BG; Kar S; Reed GL
    Am J Cardiovasc Drugs; 2015 Aug; 15(4):275-85. PubMed ID: 25782437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).
    Stone GW; Clayton T; Deliargyris EN; Prats J; Mehran R; Pocock SJ
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):15-20. PubMed ID: 24140664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial).
    Lansky AJ; Mehran R; Cristea E; Parise H; Feit F; Ohman EM; White HD; Alexander KP; Bertrand ME; Desmet W; Hamon M; Stone GW
    Am J Cardiol; 2009 May; 103(9):1196-203. PubMed ID: 19406258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
    Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
    Wang H; Li Y; Cong H; Ding S; Liu B; Li L; Chen Y; Jia S; Jing Q; Zhao X; Liu H; Liang Z; Li J; Bao D; Han Y
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1157-1165. PubMed ID: 27677411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
    Parodi G; Antoniucci D; Nikolsky E; Witzenbichler B; Guagliumi G; Peruga JZ; Stuckey T; Dudek D; Kornowski R; Hartmann F; Lansky AJ; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2010 Aug; 3(8):796-802. PubMed ID: 20723849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.
    Shah A; Feldman DN
    Vasc Health Risk Manag; 2012; 8():115-23. PubMed ID: 22399856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.
    Gurm HS; Sarembock IJ; Kereiakes DJ; Young JJ; Harrington RA; Kleiman N; Feit F; Wolski K; Bittl JA; Wilcox R; Topol EJ; Lincoff AM
    J Am Coll Cardiol; 2005 Jun; 45(12):1932-8. PubMed ID: 15963389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
    J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.